Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)

References

• Ozcakir S, Sivrioglu K. Botulinum toxin in poststroke spasticity. Clin Med Res 2007;5:132-8
   PubMedGoogle Scholar
• Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm 2008;115:607-16
   PubMed Web of Science ®Google Scholar
• Vanek ZF, Menkes JH. Spasticity. Medscape. New York, NY: WebMD, 2012. Available at: http://emedicine.medscape.com/article/1148826-overview#aw2aab6b3 [Last accessed 05 June 2014]
   Google Scholar
• Brin MF. Preface. Muscle Nerve Suppl 1997;6:S1
   Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-54
   PubMed Web of Science ®Google Scholar
• Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology 2013;80:S13-19
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Albanese A, Chancellor MB, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon 2013;67:115-28
   PubMed Web of Science ®Google Scholar
• Simpson DM, Gracies JM, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-8
   PubMed Web of Science ®Google Scholar
• Ward AB, Aguilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity–a European consensus statement. J Rehabil Med 2003;35:98-9
   PubMed Web of Science ®Google Scholar
• Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25
   PubMed Web of Science ®Google Scholar
• Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin 2008;26(1 Suppl):54-65
   Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-17
   PubMed Web of Science ®Google Scholar
• Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003;60:1186-8
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400
   PubMed Web of Science ®Google Scholar
• Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;32:259-65
   PubMed Web of Science ®Google Scholar
• Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 2011;43:486-92
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-65
   PubMed Web of Science ®Google Scholar
• Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21
   PubMed Web of Science ®Google Scholar
• Brashear A, McAfee AL, Kuhn ER, et al. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85:705-9
   PubMed Web of Science ®Google Scholar
• Childers MK, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85:1063-9
   PubMed Web of Science ®Google Scholar
• Hesse S, Reiter F, Konrad M, et al. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-8
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300
   PubMed Web of Science ®Google Scholar
• Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10
   PubMed Web of Science ®Google Scholar
• Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 2005;27:176-84
   PubMed Web of Science ®Google Scholar
• Elia AE, Filippini G, Calandrella D, et al. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009;24:801-12
   PubMed Web of Science ®Google Scholar
• Zorowitz RD, Gillard PJ, Brainin M. Poststroke spasticity: sequelae and burden on stroke survivors and caregivers. Neurology 2013;80:S45-52
   PubMed Web of Science ®Google Scholar
• Sturm JW, Donnan GA, Dewey HM, et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004;35:2340-5
   PubMed Web of Science ®Google Scholar
• Elovic E, Brashear A, Kaelin D, et al. The effect of repeated treatment of botulinum toxin type A on poststroke, spasticity-related pain: a subgroup analysis of patients in a 12-month trial. Neurology 2007;68:A177 ABS-P04.131, IN10-1.008 (abstract)
   Google Scholar
• Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol 2009;16(2 Suppl):2-5
   Google Scholar
• Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 2012;15:419-23
   PubMedGoogle Scholar